Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 1 of 33 · 1551 articles
Subtopics
Many people with IBD also have inflammatory joint disease. This combined clinic model aimed to provide simultaneous gastroenterology and rheumatology assessment and shared decision-making, and the study reports frequent...
This change may make starting Skyrizi more convenient for adults with Crohn's disease by allowing subcutaneous induction at home using an on‑body injector, rather than requiring clinic IV infusions. It also represents an...
IUS can provide rapid, bedside assessment and longitudinal monitoring of IBD activity, which may improve treat-to-target care. Understanding barriers and strategies for implementation matters for patients and clinicians...
A transcriptomic "barrier-injury" score that tracks mucosal inflammation and predicts lower odds of mucosal healing could help researchers develop biomarkers for patient stratification, prognosis, or as exploratory...
The study suggests commonly available lab tests might help identify intestinal fibrosis and strictures in Crohn’s disease using a five-marker blood-based model, which could offer a noninvasive screening option if...
The updated official label affects dosing options, monitoring, and safety information for guselkumab in people with Crohn’s disease and ulcerative colitis, which can influence treatment decisions and routine testing.
If you have Crohn’s disease with perianal fistulas and are treated with infliximab, this study suggests the drug is cleared faster and trough levels are often lower after standard dosing — which may mean you need higher...
Patients and clinicians want blood or noninvasive tests that reflect what is seen on colonoscopy. This study identifies XCL1 as a blood biomarker candidate associated with endoscopic activity in Crohn's disease, though...
Accurate diagnosis and classification affect treatment choices and risks—misdiagnosis can lead to unnecessary immunosuppression, while misclassification can under-recognize severe or proximal disease that needs different...
Validated patient-reported measures help track how IBD affects daily function and well-being. A Turkish IBD-Disk gives clinicians and researchers a standardized way to measure patient-perceived disease burden and monitor...
The endoplasmic reticulum helps control cell metabolism and is implicated in conditions including metabolic disorders, cancer, and inflammatory diseases such as Crohn’s disease.
Postoperative intra-abdominal abscesses are a common, serious short-term complication after ileocecal surgery in children with Crohn’s disease and can lengthen hospital stay and delay restarting medical treatment.
This analysis suggests delivery method for the same anti‑TNF (infliximab) may affect long‑term clinical and endoscopic outcomes in ileal-predominant Crohn’s disease. If confirmed, route of maintenance dosing could...
An FDA approval of a subcutaneous induction option for risankizumab means adults with moderate-to-severe Crohn's disease can start treatment at home using an on-body injector, which may make starting therapy more...
Definitions of "disease burden" vary a lot, which makes it hard to compare studies or to ensure care and research address what matters most to people with Crohn's. A unified, multidimensional framework could help...
Long waits for IBD-related surgery were linked to poorer quality of life in this study, especially when waiting exceeded 1 year. That suggests delays could meaningfully affect daily functioning for people with Crohn’s or...
Hospitalized patients with moderate-to-severe ulcerative colitis flares sometimes need escalation to biologic or surgical treatments. This trial is testing whether a short course of HBOT can improve symptoms and reduce...
NUDT15 gene variants can strongly increase the risk of neutropenia from thiopurine drugs used in IBD. Knowing a child’s NUDT15 status could help prevent serious low white blood cell counts by guiding drug choice or...
Reliable, low‑cost lab methods to measure mesalazine in tablets help ensure pharmaceutical quality and correct dosing of 5‑ASA drugs used in ulcerative colitis and IBD.
This study maps gene and microRNA changes linked to ulcerative colitis and tests how deleting STAT6 or treating mice with Corylus avellana extract shifts those molecular signatures. Identifying such molecular players may...
If baseline mucosal gene-expression patterns can identify patients more likely to achieve mucosal healing across drug classes, those patterns could eventually help personalize treatment selection or stratify patients in...
Long-term Phase 3 extension data suggest guselkumab (Tremfya) can sustain clinical and endoscopic remission through three years for some patients with Crohn’s disease.
This study addresses a common problem in Crohn's patients on infliximab: low drug levels despite IV dosing. It suggests switching to a subcutaneous infliximab formulation can raise and stabilize trough concentrations...
If oral microbes can influence the gut, that could open new ways to monitor or modify disease activity in IBD (for example saliva-based biomarkers or oral-targeted interventions). It also highlights modifiable factors...
The study asks whether hospitalized IBD patients have longer QT intervals—information that could affect assessment of arrhythmia risk or monitoring when prescribing QT-prolonging drugs.
A positive stool screening test requires diagnostic colonoscopy to check for colorectal cancer or other treatable conditions. Understanding why some people skip follow-up helps programs reduce missed diagnoses and...
A reusable transcriptomic atlas could let researchers compare new IBD biopsy datasets to a common reference, improving cross-study comparisons and helping separate inflammation from persistent disease-state biology that...
A simple blood test (CRP) that's already used in IBD care might help predict which Crohn's patients with C. difficile coinfection are more likely to need intestinal surgery, enabling earlier attention or monitoring.
The findings describe a novel cell‑based IL‑10 delivery strategy that reduced experimental colitis and altered gut microbiota—an approach that could inform future IBD therapies research.
Malnutrition is common in IBD and linked to worse quality of life and outcomes. Validating a standardized GLIM approach could help clinicians identify and treat malnutrition earlier and more consistently in people with...
People with Crohn’s disease who have had, or will have, intestinal surgery may benefit from better tools to predict early complications and endoscopic recurrence. Predictive models could help tailor follow-up and...
People with IBD and coexisting primary sclerosing cholangitis (PSC) are at higher colorectal neoplasia risk and may respond differently to IBD medicines. This meta-analysis compiles available evidence on commonly used...
People with PSC who undergo liver transplant — especially those who have IBD at the time of transplant — remain at elevated risk for colorectal neoplasia, IBD flare or new-onset IBD, and for PSC recurrence. Knowing this...
Reports effectiveness and safety of risankizumab specifically in East Asian participants from global phase 2b/3 UC trials, which may inform regional applicability of trial results for people with moderate-to-severe...
IBD is linked to higher skeletal risk; early biochemical changes in Wnt-pathway proteins might identify bone impairment before DXA detects low bone density, potentially helping earlier risk stratification.
If you have moderate-to-severe UC and are treated with adalimumab (or other therapies), this study suggests the rectum may be slower or less likely to reach endoscopic and histologic healing than more proximal colon...
These patient-derived human tissue models aim to let drug developers test whether a candidate affects disease-relevant biology in human intestinal tissue before moving to clinical trials, which could help reduce failures...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Tests and monitoring. The original article is from Middle East journal of digestive diseases.
Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Crohn's & colitis 360.
Children with Crohn’s disease may have vitamin D deficiency and a theoretical link between vitamin D levels and relapse risk; this trial tested whether adding high‑dose vitamin D3 at diagnosis could lower relapses and...
Distinguishing inflammation from irreversible fibrosis is a common clinical challenge in Crohn’s disease because it affects treatment choices (medical therapy versus surgery). Validated MRI biomarkers could improve...
Cure8 found this source from chicagobusiness.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full...
The study suggests Crohn’s disease is associated with coordinated brain structure and function differences that relate to disease activity and quality of life, pointing to brain–gut links that could inform future...
Identifying genes and pathways involved in IBD can point to new biological mechanisms, potential biomarkers, and future targets for research that may eventually inform diagnosis or treatment.
This trial tested a new monoclonal antibody directed at TLR3 in moderate-to-severe ulcerative colitis to see if it is safe and biologically active.
Parents and clinicians often worry about liver disease when children are diagnosed with Crohn's. This study suggests advanced liver fibrosis is uncommon at diagnosis, but elastography and fibrotic biomarkers can be...
This study suggests a relationship between higher ustekinumab trough concentrations and clinical remission in adults with Crohn’s disease, which could be relevant to patients and clinicians considering drug-level...
Noninvasive biomarkers that predict response to anti‑TNF drugs could help personalize treatment decisions and identify early who will achieve long‑term endoscopic remission.
